Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Ocaratuzumab> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- Ocaratuzumab abstract "Ocaratuzumab (AME-133v, LY2469298) is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.Phase I/II trials in relapsed/refractory follicular lymphoma have been completed in the United States (US) and Japan, and a Phase I trial was conducted in US rheumatoid arthritis patients. Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following currently available treatments, and a significant need for new effective treatment exists, particularly for patients with low-affinity FcγRIIIa allotypes. In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as compared to rituximab. Additional development in other oncology and rheumatology indications will also be pursued, as well as subcutaneous formations for patient convenience.This drug is currently being developed by Mentrik Biotech, LLC.".
- Ocaratuzumab atcPrefix "none".
- Ocaratuzumab casNumber "1169956-08-4".
- Ocaratuzumab wikiPageID "35610497".
- Ocaratuzumab wikiPageRevisionID "587857560".
- Ocaratuzumab atcPrefix "none".
- Ocaratuzumab c "6464".
- Ocaratuzumab casNumber "1169956".
- Ocaratuzumab chemspiderid "NA".
- Ocaratuzumab h "10016".
- Ocaratuzumab hasPhotoCollection Ocaratuzumab.
- Ocaratuzumab molecularWeight "145.3".
- Ocaratuzumab n "1712".
- Ocaratuzumab o "2010".
- Ocaratuzumab s "44".
- Ocaratuzumab source "zu".
- Ocaratuzumab target CD20.
- Ocaratuzumab type "mab".
- Ocaratuzumab subject Category:Monoclonal_antibodies.
- Ocaratuzumab type Abstraction100002137.
- Ocaratuzumab type Antibody115027189.
- Ocaratuzumab type Chemical114806838.
- Ocaratuzumab type Compound114818238.
- Ocaratuzumab type Macromolecule114944888.
- Ocaratuzumab type Material114580897.
- Ocaratuzumab type Matter100020827.
- Ocaratuzumab type Molecule114682133.
- Ocaratuzumab type MonoclonalAntibodies.
- Ocaratuzumab type MonoclonalAntibody115029781.
- Ocaratuzumab type OrganicCompound114727670.
- Ocaratuzumab type Part113809207.
- Ocaratuzumab type PhysicalEntity100001930.
- Ocaratuzumab type Protein114728724.
- Ocaratuzumab type Relation100031921.
- Ocaratuzumab type Substance100019613.
- Ocaratuzumab type Thing100002452.
- Ocaratuzumab type Unit109465459.
- Ocaratuzumab type Drug.
- Ocaratuzumab type FunctionalSubstance.
- Ocaratuzumab comment "Ocaratuzumab (AME-133v, LY2469298) is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders.".
- Ocaratuzumab label "Ocaratuzumab".
- Ocaratuzumab label "أوكاراتوزوماب".
- Ocaratuzumab sameAs m.0jkw1c8.
- Ocaratuzumab sameAs Q7075663.
- Ocaratuzumab sameAs Q7075663.
- Ocaratuzumab sameAs Ocaratuzumab.
- Ocaratuzumab wasDerivedFrom Ocaratuzumab?oldid=587857560.
- Ocaratuzumab isPrimaryTopicOf Ocaratuzumab.